Cell Therapies

We are interested in various stem-cell and immune-cell therapies, including indication expansion of chimeric antigen receptor (CAR) T-cell therapies within hematological malignancies. We support innovative start-ups improving the immunogenic profiles of therapies and reducing the burden of complex manufacturing and long treatment timelines.